These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33109571)

  • 41. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
    Huang J; Wang X; Wen G; Ren Y
    Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Expression of S100A2 in secondarily radioresistant pancreatic cancer cells and significance thereof].
    Wen Q; Zhao YP; Chen G; Zhang FQ; Zhang TP
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(40):2817-20. PubMed ID: 17200013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Downregulation of the long noncoding RNA TUG1 inhibits the proliferation, migration, invasion and promotes apoptosis of renal cell carcinoma.
    Zhang M; Lu W; Huang Y; Shi J; Wu X; Zhang X; Jiang R; Cai Z; Wu S
    J Mol Histol; 2016 Aug; 47(4):421-8. PubMed ID: 27323757
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.
    Taniguchi H; Ito S; Ueda T; Morioka Y; Kayukawa N; Ueno A; Nakagawa H; Fujihara A; Ushijima S; Kanazawa M; Hongo F; Ukimura O
    Biochem Biophys Res Commun; 2017 Apr; 485(2):267-271. PubMed ID: 28235487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
    Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
    Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma.
    Tsai WC; Tsai ST; Jin YT; Wu LW
    Mol Cancer Res; 2006 Aug; 4(8):539-47. PubMed ID: 16908593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma.
    Li P; Liu J; Li J; Liu P
    Mol Biol Rep; 2019 Aug; 46(4):4377-4383. PubMed ID: 31147860
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aberrant Methylation of the 1p36 Tumor Suppressor Gene RIZ1 in Renal Cell Carcinoma.
    Ge P; Yu X; Wang ZC; Lin J
    Asian Pac J Cancer Prev; 2015; 16(9):4071-5. PubMed ID: 25987089
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma.
    Hirata H; Hinoda Y; Nakajima K; Kawamoto K; Kikuno N; Ueno K; Yamamura S; Zaman MS; Khatri G; Chen Y; Saini S; Majid S; Deng G; Ishii N; Dahiya R
    Int J Cancer; 2011 Apr; 128(8):1793-803. PubMed ID: 20549706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma.
    Imazawa M; Hibi K; Fujitake S; Kodera Y; Ito K; Akiyama S; Nakao A
    Anticancer Res; 2005; 25(2B):1247-50. PubMed ID: 15865073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
    Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
    Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.
    Peters I; Dubrowinskaja N; Hennenlotter J; Antonopoulos WI; Von Klot CAJ; Tezval H; Stenzl A; Kuczyk MA; Serth J
    Oncol Rep; 2018 Dec; 40(6):3861-3868. PubMed ID: 30272321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Down-regulation of S100A2 in lymph node metastases of head and neck cancer.
    Zhang X; Hunt JL; Shin DM; Chen ZG
    Head Neck; 2007 Mar; 29(3):236-43. PubMed ID: 17123307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
    Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
    Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.
    Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P
    Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features.
    Wang L; Cui Y; Zhang L; Sheng J; Yang Y; Kuang G; Fan Y; Zhang Q; Jin J
    PLoS One; 2016; 11(9):e0161859. PubMed ID: 27583477
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigenetic inactivation of the candidate tumor suppressor gene ASC/TMS1 in human renal cell carcinoma and its role as a potential therapeutic target.
    Liu Q; Jin J; Ying J; Cui Y; Sun M; Zhang L; Fan Y; Xu B; Zhang Q
    Oncotarget; 2015 Sep; 6(26):22706-23. PubMed ID: 26093088
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Clinicopathological Significance of Epigenetic Silencing of VHL Promoter and Renal Cell Carcinoma: A Meta-Analysis.
    Yang L; Zhao Z; Zhao S; Chen C; Cong X; Li Z; Ren M
    Cell Physiol Biochem; 2016; 40(6):1465-1472. PubMed ID: 27997886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.